Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × pCR Rate × Epirubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 15 Stomach Neoplasms 6 Neoplasms 2 Inflammatory Breast Neoplasms 2 Esophageal Neoplasms 2 pCR Rate 1 Triple Negative Breast Neoplasms 1 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Rhabdomyosarcoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Oesophago-gastric Cancer 1 Neoplasms, Germ Cell and Embryonal 1 Nasopharyngeal Carcinoma 1 Epstein-Barr Virus Infections 1 Cardiotoxicity 1 Breast Neoplasms, Male 1

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡